Prof Joseph Trapani
Director, Centre for Cancer Immunotherapy
The Sir Peter MacCallum Department of Oncology
439 Scholarly works
35 Projects
HIGHLIGHTS
2026
Journal article
A TAK1 cytokine toxicity checkpoint controls anti-cancer immunity
DOI: 10.1016/j.celrep.2025.1166652025
Journal article
Hypoxia and IL-15 Cooperate to Induce Perforin Expression by CD8 T Cells and Promote Damage to the Skin in Murine Cutaneous Leishmaniasis
DOI: 10.1016/j.jid.2025.04.0292025
Journal article
DLBCL tumor microenvironment archetype and CD4 T cell conversion to cytotoxic cells are required for response to glofitamab
DOI: 10.1182/blood-2025-5572025
Journal article
Targeting PTPN2 enhances human CAR T cell efficacy and the development of long-term memory in mouse xenograft models
DOI: 10.1126/scitranslmed.adk06272020
Research grants (ARC, NHMRC, MRFF)
Immunobiology of Cancer and New Cancer Treatments
2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
2018
Research Grant
Immunobiology and Immunotherapy of Cancer
RECENT SCHOLARLY WORKS
2025
Journal article
MON-312 Lewis Y Antigen as a Novel Target for CAR (Chimeric Antigen Receptor) T-cell Therapy in Patients with Neuroendocrine Prostate Cancer
DOI: 10.1210/jendso/bvaf149.24122025
Journal article
A CDK11-dependent RNA polymerase II pause-checkpoint precedes CDK9-mediated transition to transcriptional elongation
DOI: 10.1016/j.molcel.2025.08.0012025
Journal article
197 | CD4 T CELL RECRUITMENT AND DIFFERENTIATION INTO A CYTOTOXIC PHENOTYPE IS ASSOCIATED WITH THE TREATMENT OF PATIENTS WITH GLOFITAMAB TOGETHER WITH R‐CHOP OR POLA‐R‐CHP
DOI: 10.1002/hon.70094_1972025
Journal article
CARBOPLATIN ENHANCES RESPONSE TO CAR T CELL THERAPY THROUGH MACROPHAGE RECRUITMENT AND POLARISATION IN SOLID TUMORS
DOI: 10.1016/j.jcyt.2025.03.3712025
Journal article
Acidic pH can attenuate immune killing through inactivation of perforin
DOI: 10.1038/s44319-024-00365-62025
Journal article
Lewis Y antigen as a novel target for CAR (chimeric antigen receptor) T-cell therapy in patients with neuroendocrine prostate cancer.
DOI: 10.1200/jco.2025.43.5_suppl.217
RECENT PROJECTS
2024
Research grants (other domestic)
How to Curb Cytokine Release Syndrome in Patients Undergoing Immunotherapy
2022
Research grants (ARC, NHMRC, MRFF)
mRNA-based Antiviral Therapeutics for SARS-CoV-2 Using Cas13